China News Agency, Beijing, February 14 (Reporter Chen Kangliang) China's A-shares performed relatively stable on the 14th (Tuesday), and the major stock indexes rose and fell each other.
The traditional Chinese medicine sector performed brilliantly that day, leading the gains.
According to data from the financial data service provider Flush, the traditional Chinese medicine sector rose by 1.45% that day, and the cumulative increase this week was 2.81%, outperforming the Shanghai Composite Index over the same period.
In terms of individual stocks, the stock prices of Longshen Rongfa, Dali Pharmaceutical, Zuoli Pharmaceutical, and Fangsheng Pharmaceutical all rose by more than 5%.
Recently, China officially issued special regulations on the registration and management of traditional Chinese medicines (hereinafter referred to as special regulations), which will come into force on July 1, 2023.
There are 82 special regulations in 11 chapters, which further refine the requirements for the development of traditional Chinese medicine, strengthen the management of new drug development and registration of traditional Chinese medicine, and promote the inheritance, innovation and development of traditional Chinese medicine.
Lin Xiaowei, an analyst at Everbright Securities, said that the implementation of special regulations will promote the upgrading of the traditional Chinese medicine industry, and the reform of the supply side of traditional Chinese medicine is expected to accelerate the implementation.
The special regulations are more standardized and practical. The regulations clearly promote the development and innovation of new traditional Chinese medicines, and give priority to the review and approval of registration applications for new traditional Chinese medicines with clear clinical positioning and obvious clinical value. It is expected that the clinical value of new traditional Chinese medicines will Effective improvement, the progress of R&D approval is expected to be accelerated, and it is expected to promote the improvement of the quality of traditional Chinese medicine and industrial upgrading.
Zhu Guoguang, an analyst at Soochow Securities, believes that after the introduction of special regulations, the registration classification and listing approval of traditional Chinese medicine, the rational application of human experience evidence, innovative traditional Chinese medicine, improved new medicine of traditional Chinese medicine, and compound preparations of traditional Chinese medicine with ancient classic prescriptions will become more specific. The development direction of traditional Chinese medicine enterprises will also be clearer, which is expected to promote the application and approval of innovative traditional Chinese medicine enterprises, which will benefit related enterprises.
In terms of the overall performance of the market that day, as of the close, the Shanghai Composite Index reported 3293 points, an increase of 0.28%, with a turnover of 355.6 billion yuan (RMB, the same below); the Shenzhen Component Index reported 12094 points, a decrease of 0.15%, with a turnover of 558.4 billion yuan yuan; the ChiNext Index reported 2565 points, down 0.31%.
(over)